Chronos announces positive pre-clinical results for the lead compound in its DAT inhibitor programme in an in vivo model of fatigue in multiple sclerosis (MS). Read the press release.
A second patent application for novel orexin 1 antagonists has been filed on 25 October 2017. This is an entirely new composition of matter patent supporting our binge eating disorder and alcohol [...]
Chronos CEO, CSO and VP Corporate Development were interviewed at The Telegraph studios recently. Click here to see the interview on our approach to degenerative and behavioural brain disease.
A patent application for our novel orexin 1 antagonist has been filed on 1 September 2017. This is an entirely new composition of matter patent supporting our binge eating disorder and alcohol [...]
See the interview here.
Chronos CEO, Dr Huw Jones has been awarded best CEO in the European drug discovery industry by online and print magazine European CEO. Read the press release.
Dr Schulz-Utermoehl has over 17 years’ experience in the pharmaceutical industry, spanning early and late-stage discovery research and pre-clinical development. He and Dr Fraser Murray will be [...]
Dr Murray brings more than 20 years’ of drug discovery and early development experience across a range of therapeutic areas, including neurodegeneration, psychiatry, inflammation and [...]